busulfan has been researched along with Agnogenic Myeloid Metaplasia in 132 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dibromomannitol (DBM) is a new agent for the treatment of chronic granulocytic leukemia." | 9.04 | Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan. ( Canellos, GP; DeVita, VT; Neiman, PE; Young, RC, 1975) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 7.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "Idiopathic myelofibrosis is a disease of unknown cause characterized by systemic marrow fibrosis and extramedullary hematopoiesis." | 5.28 | [Successful treatment of primary myelofibrosis by busulfan pulse therapy: report of a case]. ( Iwahara, Y; Kataoka, R; Miyoshi, I; Muneishi, H; Uemura, Y, 1990) |
| "From 2002 to 2007, 103 patients with primary myelofibrosis or postessential thrombocythemia and polycythemia vera myelofibrosis and a median age of 55 years (range, 32-68 years) were included in a prospective multicenter phase 2 trial to determine efficacy of a busulfan (10 mg/kg)/fludarabine (180 mg/m(2))-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation from related (n = 33) or unrelated donors (n = 70)." | 5.14 | Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. ( Baurmann, H; Bethge, W; Bornhäuser, M; Brand, R; Burchert, A; Corradini, P; de Witte, TM; Dreger, P; Einsele, H; Holler, E; Kaufmann, M; Kobbe, G; Kröger, N; Kvasnicka, HM; Nagler, A; Niederwieser, D; Schubert, J; Schwerdtfeger, R; Stelljes, M; Thiele, J; Uharek, L; Wandt, H; Wulf, GG; Zabelina, T; Zander, AR, 2009) |
| "Dibromomannitol (DBM) is a new agent for the treatment of chronic granulocytic leukemia." | 5.04 | Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan. ( Canellos, GP; DeVita, VT; Neiman, PE; Young, RC, 1975) |
| " We aimed to identify the risk factors that predict transplantation outcomes in patients with MF who underwent matched or mismatched allo-SCT using a uniform myeloablative conditioning regimen consisting of busulfan and fludarabine with tacrolimus and methotrexate-based graft-versus-host disease prophylaxis." | 4.31 | Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. ( Alousi, AM; Bashir, Q; Champlin, RE; Hosing, C; Joseph, J; Kebriaei, P; Milton, DR; Olson, AL; Oran, B; Popat, UR; Qazilbash, MH; Ramdial, JL; Saini, NY; Shpall, EJ; Srour, SA, 2023) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 3.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "Diagnosis was primary myelofibrosis in 18 patients and secondary myelofibrosis in 6 patients; in 4 of them, primary myelofibrosis evolved from polycythemia vera, and in 2 of them from essential thrombocythemia." | 2.73 | Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. ( Bethge, W; Bornhäuser, M; de Witte, T; Kobbe, G; Kröger, N; Kvasnicka, HM; Schubert, J; Schwerdtfeger, R; Thiele, J; Zander, A, 2007) |
| "Current therapeutic options for myeloid metaplasia with myelofibrosis (MMM) are limited." | 2.70 | Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. ( Anderson, JE; Appelbaum, FR; Callander, N; Chauncey, T; Craig, F; Deeg, HJ; Freytes, C; Gazitt, Y; Guardiola, P; Holmberg, L; Razvillas, B; Tefferi, A, 2001) |
| "To assess the dynamics of myelofibrosis more precisely, computation of differences in the degree of fiber density between the first and last examination was carried out." | 2.68 | The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML--a comparative morphometric study on sequential trephine biopsies. ( Dammasch, J; Diehl, V; Kloke, O; Kvasnicka, HM; Leder, LD; Meuter, BR; Niederle, N; Schmidt, M; Thiele, J; Zirbes, TK, 1995) |
| "Primary myelofibrosis is a stem cell-derived clonal malignancy characterized by unchecked proliferation of myeloid cells, resulting in bone marrow fibrosis, osteosclerosis, and pathologic angiogenesis." | 2.52 | Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications. ( Daver, N; Khoury, JD; Nazha, A; Rampal, RK, 2015) |
| "Development of myelofibrosis in IMF is obviously due to disease progression unrelated to stage at diagnosis and not significantly influenced by treatment modalities." | 2.42 | Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis. ( Diehl, V; Hülsemann, R; Kvasnicka, HM; Schmitt-Gräff, A; Thiele, J, 2004) |
| "We report a case of myelofibrosis with myeloid metaplasia (MMM) that responded dramatically to oral busulfan treatment after failure of hydroxyurea." | 2.41 | Myelofibrosis: response to busulfan after hydroxyurea failure. ( Baumann, MA; Naqvi, T, 2002) |
| "Idiopathic myelofibrosis is reviewed from several aspects." | 2.38 | Idiopathic myelofibrosis: historical review, diagnosis and management. ( Weinstein, IM, 1991) |
| "The case of a patient with myelofibrosis who developed polycythaemia vera after corticosteroid therapy, splenectomy and Busulphan therapy is reported." | 2.37 | [Onset of polycythemia in idiopathic myelofibrosis. Description of a clinical case and review of the literature]. ( Bizzi, B; Leone, G; Marra, R; Pagano, L; Rabbitti, C; Storti, S; Teofili, L, 1988) |
| "We analyzed 120 patients with myelofibrosis, for whom chimerism data were available on day +30." | 1.62 | Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen. ( Angelucci, E; Bacigalupo, A; Barosi, G; Bregante, S; Casarino, L; Chiusolo, P; De Stefano, V; Di Grazia, C; Dominietto, A; Giammarco, S; Gualandi, F; Guolo, F; Lamparelli, T; Laurenti, L; Metafuni, E; Raiola, AM; Rossi, E; Rossi, M; Sica, S; Signori, A; Sora, F; Vannucchi, A, 2021) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "We report 14 patients affected by myelofibrosis with a median age of 57 years (range, 41-76) receiving a treosulfan-fludarabine based reduced toxicity conditioning." | 1.43 | Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. ( Assanelli, A; Bernardi, M; Carrabba, M; Ciceri, F; Claudiani, S; Corti, C; De Freitas, T; Giglio, F; Guggiari, E; Lunghi, F; Lupo-Stanghellini, MT; Marcatti, M; Marktel, S; Peccatori, J; Piemontese, S, 2016) |
| "This study indicates that in myelofibrosis, NMA regimens result in high engraftment failure rates." | 1.42 | Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis. ( Broers, AE; Janssen, JJ; Raymakers, R; Slot, S; Smits, K; Te Boekhorst, PA; van de Donk, NW; Witte, BI; Zweegman, S, 2015) |
| "We report the results of 11 patients myelofibrosis, who have received a uniform alemtuzumab-based RIC HSCT." | 1.37 | Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis. ( Abdullah, A; Ho, AY; Kenyon, M; Krishnamurthy, P; Lea, N; Lim, ZY; Marsh, J; Mufti, GJ; Nagi, W; Pagliuca, A; Potter, V; Reiff-Zall, L; Tindell, V, 2011) |
| "Since bone marrow biopsy revealed myelofibrosis, she received anabolic hormone therapy." | 1.35 | [Long-term remission of non-Hodgkin lymphoma secondary to the treatment for essential thrombocythemia]. ( Kubota, Y; Waki, M, 2009) |
| "Controversial issues in chronic idiopathic myelofibrosis (IMP) are amongst others the evolution of the disease process and the influence of therapy on the dynamics of fibrosis." | 1.32 | Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. ( Diehl, V; Kvasnicka, HM; Schmitt-Graeff, A; Thiele, J, 2003) |
| "Agnogenic myeloid metaplasia (AMM) is a clonal hematopoietic stem cell disorder characterized by bone marrow fibrosis, extramedullary hemopoiesis, splenomegaly and a leukoerythroblastic blood picture." | 1.32 | Reversal of marrow fibrosis in agnogenic myeloid metaplasia by allogeneic peripheral blood stem cell transplantation. ( Issaragrisil, S; Sangruchi, T; Udomsakdi-Auewarakul, C; Visuthisakchai, S, 2003) |
| "Hydroxyurea and myelosan were mostly used as cytostatic drugs while erythrocyte mass transfusions and hemoexfusions (phlebotomy)--for life-support." | 1.32 | [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases]. ( Pop, VP; Rukavitsyn, OA; Seriakov, AP, 2004) |
| "Three patients with myelofibrosis received allogeneic stem cell transplantation after a dose-reduced conditioning regimen of busulphan (8 mg/kg), fludarabine (180 mg/m2) and antithymocyte globulin (4 x 10 mg/kg)." | 1.31 | Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. ( Ayuk, FA; Erttmann, R; Hansen, A; Hessling, J; Kordes, U; Kröger, N; Panse, J; Renges, H; Werner, M; Zabelina, T; Zander, AR, 2002) |
| "Of the 124 patients without myelofibrosis at onset, 42% later transformed into the myelofibrotic subtype." | 1.31 | Changing patterns of histological subgroups during therapy of Ph1+ chronic myelogenous leukaemia. ( Kvasnicka, HM; Leder, LD; Schaefer, HE; Schmitt-Graeff, A; Thiele, J, 2000) |
| "Idiopathic myelofibrosis is a disease of unknown cause characterized by systemic marrow fibrosis and extramedullary hematopoiesis." | 1.28 | [Successful treatment of primary myelofibrosis by busulfan pulse therapy: report of a case]. ( Iwahara, Y; Kataoka, R; Miyoshi, I; Muneishi, H; Uemura, Y, 1990) |
| "A 20-year-old male with chronic myelogenous leukemia (CML) and severe bone marrow fibrosis underwent splenectomy, then ablative chemotherapy, followed by bone marrow transplantation from a histocompatible sister." | 1.27 | The reversal of myelofibrosis associated with chronic myelogenous leukemia after allogeneic bone marrow transplantation. ( Braylan, RC; Elfenbein, GJ; Jones, J; Oblon, DJ; Weiner, RS, 1983) |
| "14 patients with essential thrombocythemia (ET) and 1 patient with agnogenic myeloid metaplasia received (1-(2-chloroethyl)-cyclohexyl-nitrosourea (CCNU), 80 mg/m2, p." | 1.27 | 1-(2-Chloroethyl)-cyclohexyl-nitrosourea-induced remission in essential thrombocythemia. ( Grossi, A; Leoni, F; Rossi Ferrini, P, 1983) |
| "12 patients with symptomatic chronic myelofibrosis were treated with either busulphan or 6-thioguanine." | 1.27 | Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. ( Manoharan, A; Pitney, WR, 1984) |
| "When busulfan treatment was resumed, hematologic response and decrease of hepatomegaly and splenomegaly reoccurred." | 1.27 | Remission of chronic idiopathic myelofibrosis to busulfan treatment. ( Chang, JC; Gross, HM, 1988) |
| "The Authors present a case of acute myeloblastic leukemia secondary to a busulfan and splenic radiotherapy treated idiopathic myelofibrosis." | 1.27 | [Acute leukemia secondary to idiopathic myelofibrosis with homozygote pseudo-Pelger anomaly and complex chromosomal changes]. ( Bartolomei, P; Bortotto, L; Fossaluzza, V; Tosato, F, 1986) |
| "Only deaths from acute leukaemia and myelofibrosis were significantly increased above the normal population incidence." | 1.27 | Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. ( Messinezy, M; Pearson, TC; Prochazka, A; Wetherley-Mein, G, 1985) |
| "A case of typical idiopathic myelofibrosis turning into polycythaemia vera 6 years after diagnosis is reported." | 1.27 | [Development of polycythemia vera during chronic idiopathic myelofibrosis]. ( Covaz, E; Mazzanti, G; Paladini, G; Tosato, F, 1985) |
| "A patient with PNH and myelofibrosis appearing simultaneously is presented." | 1.26 | Response to busulphan treatment of paroxysmal nocturnal hemoglobinuria and myelofibrosis in one and the same patient. ( Almquist, A; Holm, J; Wahlin, A, 1981) |
| "A case of chronic myelogenous leukemia with myelofibrosis and failure to respond to busulfan therapy has been reported." | 1.26 | [New chromosome abnormality in chronic myeloid leukemia]. ( Berger, R; Gyger, M, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 79 (59.85) | 18.7374 |
| 1990's | 6 (4.55) | 18.2507 |
| 2000's | 23 (17.42) | 29.6817 |
| 2010's | 15 (11.36) | 24.3611 |
| 2020's | 9 (6.82) | 2.80 |
| Authors | Studies |
|---|---|
| Freyer, CW | 1 |
| Babushok, DV | 1 |
| Frey, NV | 1 |
| Gill, SI | 1 |
| Loren, AW | 1 |
| Luger, SM | 1 |
| Maity, A | 1 |
| Martin, ME | 1 |
| Plastaras, JP | 1 |
| Porter, DL | 1 |
| Hexner, EO | 1 |
| Murthy, GSG | 1 |
| Kim, S | 1 |
| Estrada-Merly, N | 1 |
| Abid, MB | 1 |
| Aljurf, M | 1 |
| Assal, A | 1 |
| Badar, T | 1 |
| Badawy, SM | 1 |
| Ballen, K | 1 |
| Beitinjaneh, A | 1 |
| Cerny, J | 1 |
| Chhabra, S | 2 |
| DeFilipp, Z | 1 |
| Dholaria, B | 1 |
| Perez, MAD | 1 |
| Farhan, S | 1 |
| Freytes, CO | 1 |
| Gale, RP | 1 |
| Ganguly, S | 1 |
| Gupta, V | 2 |
| Grunwald, MR | 1 |
| Hamad, N | 1 |
| Hildebrandt, GC | 1 |
| Inamoto, Y | 1 |
| Jain, T | 2 |
| Jamy, O | 1 |
| Juckett, M | 1 |
| Kalaycio, M | 1 |
| Krem, MM | 1 |
| Lazarus, HM | 1 |
| Litzow, M | 1 |
| Munker, R | 1 |
| Murthy, HS | 1 |
| Nathan, S | 1 |
| Nishihori, T | 2 |
| Ortí, G | 1 |
| Patel, SS | 1 |
| Van der Poel, M | 1 |
| Rizzieri, DA | 1 |
| Savani, BN | 1 |
| Seo, S | 1 |
| Solh, M | 1 |
| Verdonck, LF | 1 |
| Wirk, B | 1 |
| Yared, JA | 1 |
| Nakamura, R | 1 |
| Oran, B | 2 |
| Scott, B | 1 |
| Saber, W | 2 |
| Joseph, J | 1 |
| Srour, SA | 1 |
| Milton, DR | 1 |
| Ramdial, JL | 1 |
| Saini, NY | 1 |
| Olson, AL | 1 |
| Bashir, Q | 1 |
| Alousi, AM | 1 |
| Hosing, C | 1 |
| Qazilbash, MH | 1 |
| Kebriaei, P | 1 |
| Shpall, EJ | 1 |
| Champlin, RE | 1 |
| Popat, UR | 1 |
| Shouval, R | 1 |
| Vega, Y | 1 |
| Fein, JA | 1 |
| Danylesko, I | 1 |
| Shem Tov, N | 1 |
| Yerushalmi, R | 1 |
| Sobas, M | 1 |
| Czyż, A | 1 |
| Nagler, A | 2 |
| Shimoni, A | 1 |
| Schain, F | 1 |
| Vago, E | 1 |
| Song, C | 1 |
| He, J | 1 |
| Liwing, J | 1 |
| Löfgren, C | 1 |
| Björkholm, M | 1 |
| Narra, RK | 1 |
| Wu, R | 1 |
| Szabo, A | 1 |
| George, G | 1 |
| Michaelis, LC | 1 |
| D'Souza, A | 1 |
| Dhakal, B | 1 |
| Drobyski, WR | 1 |
| Fenske, TS | 1 |
| Jerkins, JH | 1 |
| Pasquini, MC | 1 |
| Rizzo, RD | 1 |
| Shah, NN | 1 |
| Shaw, BE | 1 |
| Hamadani, M | 1 |
| Hari, PN | 1 |
| Memoli, M | 1 |
| Paviglianiti, A | 1 |
| Malard, F | 1 |
| Battipaglia, G | 2 |
| Brissot, E | 1 |
| Médiavilla, C | 1 |
| Bianchessi, A | 1 |
| Banet, A | 1 |
| Van de Wyngaert, Z | 1 |
| Ledraa, T | 1 |
| Belhocine, R | 1 |
| Sestili, S | 1 |
| Lapusan, S | 1 |
| Hirsch, P | 1 |
| Favale, F | 1 |
| Boussaroque, A | 1 |
| Bonnin, A | 1 |
| Vekhoff, A | 1 |
| Legrand, O | 1 |
| Mohty, M | 3 |
| Duléry, R | 1 |
| Polverelli, N | 1 |
| Mauff, K | 2 |
| Kröger, N | 7 |
| Robin, M | 2 |
| Beelen, D | 1 |
| Beauvais, D | 1 |
| Chevallier, P | 1 |
| Passweg, J | 1 |
| Rubio, MT | 2 |
| Maertens, J | 1 |
| Finke, J | 1 |
| Bornhäuser, M | 3 |
| Vrhovac, R | 1 |
| Helbig, G | 1 |
| Mear, JB | 1 |
| Castagna, L | 1 |
| Reményi, P | 1 |
| Angelucci, E | 3 |
| Karakasis, D | 1 |
| Rifòn, J | 1 |
| Sirait, T | 1 |
| Russo, D | 2 |
| de Wreede, L | 1 |
| Czerw, T | 2 |
| Hernández-Boluda, JC | 2 |
| Hayden, P | 2 |
| McLornan, D | 2 |
| Yakoub-Agha, I | 2 |
| Chiusolo, P | 2 |
| Bregante, S | 2 |
| Giammarco, S | 1 |
| Lamparelli, T | 1 |
| Casarino, L | 1 |
| Dominietto, A | 1 |
| Raiola, AM | 1 |
| Metafuni, E | 1 |
| Di Grazia, C | 1 |
| Gualandi, F | 1 |
| Sora, F | 1 |
| Laurenti, L | 1 |
| Sica, S | 1 |
| Barosi, G | 1 |
| Guolo, F | 1 |
| Rossi, M | 1 |
| Rossi, E | 1 |
| Vannucchi, A | 1 |
| Signori, A | 1 |
| De Stefano, V | 1 |
| Bacigalupo, A | 2 |
| Wendel, L | 1 |
| Arcese, W | 1 |
| Santarone, S | 1 |
| Fox, ML | 1 |
| Blaise, D | 1 |
| Iori, AP | 1 |
| Fanin, R | 2 |
| Chalandon, Y | 1 |
| Pioltelli, P | 1 |
| Marotta, G | 1 |
| Sever, M | 1 |
| Solano, C | 1 |
| Contentin, N | 1 |
| de Wreede, LC | 1 |
| Kunze, KL | 1 |
| Temkit, M | 1 |
| Partain, DK | 1 |
| Patnaik, MS | 1 |
| Slack, JL | 1 |
| Khera, N | 1 |
| Hogan, WJ | 1 |
| Roy, V | 1 |
| Noel, P | 1 |
| Leis, JF | 1 |
| Sproat, LZ | 1 |
| Fauble, V | 1 |
| Mesa, RA | 1 |
| Palmer, J | 1 |
| Tefferi, A | 3 |
| Barbui, T | 1 |
| Patriarca, F | 1 |
| Masciulli, A | 1 |
| Pavoni, C | 1 |
| Finazzi, MC | 1 |
| Bosi, A | 1 |
| Narni, F | 1 |
| Messina, G | 1 |
| Alessandrino, EP | 1 |
| Carella, AM | 1 |
| Milone, G | 1 |
| Bruno, B | 2 |
| Mammoliti, S | 1 |
| Bonifazi, F | 1 |
| Rambaldi, A | 1 |
| Hussein, AA | 1 |
| Hamadah, T | 1 |
| Domm, J | 1 |
| Al-Zaben, A | 1 |
| Frangoul, H | 1 |
| Shanavas, M | 1 |
| Messner, HA | 1 |
| Atenafu, EG | 1 |
| Kim, DH | 1 |
| Kuruvilla, J | 1 |
| Lipton, JH | 1 |
| Uhm, J | 1 |
| Seftel, M | 1 |
| Alam, N | 1 |
| Claudiani, S | 1 |
| Marktel, S | 1 |
| Piemontese, S | 1 |
| Assanelli, A | 1 |
| Lupo-Stanghellini, MT | 1 |
| Carrabba, M | 1 |
| Guggiari, E | 1 |
| Giglio, F | 1 |
| De Freitas, T | 1 |
| Marcatti, M | 1 |
| Bernardi, M | 1 |
| Corti, C | 1 |
| Peccatori, J | 1 |
| Lunghi, F | 1 |
| Ciceri, F | 1 |
| Slot, S | 1 |
| Smits, K | 1 |
| van de Donk, NW | 1 |
| Witte, BI | 1 |
| Raymakers, R | 1 |
| Janssen, JJ | 1 |
| Broers, AE | 1 |
| Te Boekhorst, PA | 1 |
| Zweegman, S | 1 |
| Nazha, A | 2 |
| Khoury, JD | 1 |
| Rampal, RK | 1 |
| Daver, N | 1 |
| Porcher, R | 1 |
| Wolschke, C | 1 |
| Sicre de Fontbrune, F | 1 |
| Alchalby, H | 1 |
| Christopeit, M | 1 |
| Cassinat, B | 1 |
| Zabelina, T | 4 |
| Peffault de Latour, R | 1 |
| Ayuk, F | 2 |
| Socié, G | 1 |
| Gerds, AT | 1 |
| Begna, K | 1 |
| Abdelatif, A | 1 |
| Schwager, S | 1 |
| Hanson, C | 1 |
| Pardanani, A | 1 |
| Kubota, Y | 1 |
| Waki, M | 1 |
| Holler, E | 1 |
| Kobbe, G | 2 |
| Schwerdtfeger, R | 2 |
| Baurmann, H | 1 |
| Bethge, W | 2 |
| Stelljes, M | 1 |
| Uharek, L | 1 |
| Wandt, H | 1 |
| Burchert, A | 1 |
| Corradini, P | 1 |
| Schubert, J | 2 |
| Kaufmann, M | 1 |
| Dreger, P | 1 |
| Wulf, GG | 1 |
| Einsele, H | 1 |
| Kvasnicka, HM | 10 |
| Thiele, J | 10 |
| Brand, R | 1 |
| Zander, AR | 2 |
| Niederwieser, D | 1 |
| de Witte, TM | 1 |
| Takagi, S | 1 |
| Ota, Y | 1 |
| Uchida, N | 1 |
| Takahashi, K | 1 |
| Ishiwata, K | 1 |
| Tsuji, M | 1 |
| Yamamoto, H | 1 |
| Asano-Mori, Y | 1 |
| Matsuno, N | 1 |
| Masuoka, K | 1 |
| Wake, A | 1 |
| Miyakoshi, S | 1 |
| Ohashi, K | 1 |
| Taniguchi, S | 1 |
| Perkins, J | 1 |
| Kim, J | 1 |
| Field, T | 1 |
| Pidala, J | 1 |
| Roman-Diaz, J | 1 |
| Komrokji, RS | 1 |
| Fernandez, HF | 1 |
| Anasetti, C | 2 |
| Kharfan-Dabaja, MA | 1 |
| Nagi, W | 1 |
| Lim, ZY | 1 |
| Krishnamurthy, P | 1 |
| Potter, V | 1 |
| Tindell, V | 1 |
| Reiff-Zall, L | 1 |
| Abdullah, A | 1 |
| Lea, N | 1 |
| Kenyon, M | 1 |
| Marsh, J | 1 |
| Ho, AY | 1 |
| Mufti, GJ | 1 |
| Pagliuca, A | 1 |
| Hessling, J | 1 |
| Werner, M | 1 |
| Hansen, A | 1 |
| Kordes, U | 1 |
| Ayuk, FA | 1 |
| Renges, H | 1 |
| Panse, J | 2 |
| Erttmann, R | 1 |
| Buhr, T | 1 |
| Büsche, G | 1 |
| Choritz, H | 1 |
| Länger, F | 1 |
| Kreipe, H | 1 |
| Schmitt-Graeff, A | 5 |
| Diehl, V | 6 |
| Deeg, HJ | 2 |
| Gooley, TA | 1 |
| Flowers, ME | 1 |
| Sale, GE | 1 |
| Slattery, JT | 1 |
| Chauncey, TR | 1 |
| Doney, K | 1 |
| Georges, GE | 1 |
| Kiem, HP | 1 |
| Martin, PJ | 1 |
| Petersdorf, EW | 1 |
| Radich, J | 1 |
| Sanders, JE | 1 |
| Sandmaier, BM | 1 |
| Warren, EH | 1 |
| Witherspoon, RP | 1 |
| Storb, R | 1 |
| Appelbaum, FR | 2 |
| Nielsen, I | 1 |
| Hasselbalch, HC | 1 |
| CHAPTAL, J | 1 |
| JEAN, R | 1 |
| IZARN, P | 1 |
| BONNET, H | 1 |
| NAVARRO, M | 1 |
| EMBERGER, JM | 1 |
| DOCTOR, F | 1 |
| LEHOCZKY, D | 1 |
| BRODY, JI | 1 |
| MCKENZIE, D | 1 |
| KIMBALL, SG | 1 |
| SVOBODA, V | 2 |
| SILVER, RT | 1 |
| JENKINS, DE | 1 |
| ENGLE, RL | 1 |
| BOOTSMA, BK | 1 |
| MARSH, JC | 1 |
| PERRY, S | 1 |
| MOESCHLIN, S | 1 |
| MORROW, LB | 1 |
| ANDERSON, RE | 1 |
| HUNSTEIN, W | 1 |
| HARWERTH, HG | 1 |
| RAJU, S | 1 |
| PERUGINI, S | 3 |
| OISHI, N | 1 |
| SWISHER, SN | 1 |
| TROUP, SB | 1 |
| Udomsakdi-Auewarakul, C | 1 |
| Visuthisakchai, S | 1 |
| Sangruchi, T | 1 |
| Issaragrisil, S | 1 |
| Schmitt-Gräff, A | 1 |
| Hülsemann, R | 1 |
| Rukavitsyn, OA | 1 |
| Pop, VP | 1 |
| Seriakov, AP | 1 |
| Fruehauf, S | 2 |
| Buss, EC | 2 |
| Topaly, J | 1 |
| Kreipe, HH | 2 |
| Ho, AD | 2 |
| Schieder, H | 1 |
| Stute, N | 1 |
| Fehse, N | 1 |
| Waschke, O | 1 |
| Fehse, B | 1 |
| Zander, A | 2 |
| Tropaly, J | 1 |
| Merup, M | 1 |
| Lazarevic, V | 1 |
| Nahi, H | 1 |
| Andreasson, B | 1 |
| Malm, C | 1 |
| Nilsson, L | 1 |
| Brune, M | 1 |
| LeBlanc, K | 1 |
| Kutti, J | 1 |
| Birgegård, G | 1 |
| de Witte, T | 1 |
| Busuttil, DP | 1 |
| Silverstein, MN | 1 |
| Gomes, MR | 1 |
| ReMine, WH | 1 |
| Elveback, LR | 1 |
| Mey, U | 1 |
| Nix, WL | 1 |
| Fernbach, DJ | 1 |
| Oblon, DJ | 1 |
| Elfenbein, GJ | 1 |
| Braylan, RC | 1 |
| Jones, J | 1 |
| Weiner, RS | 1 |
| Leoni, F | 1 |
| Grossi, A | 1 |
| Rossi Ferrini, P | 1 |
| Manoharan, A | 3 |
| Pitney, WR | 1 |
| Hassan, K | 1 |
| Jennings, WH | 1 |
| Li, CY | 1 |
| Kiely, JM | 1 |
| Outeiriño, J | 1 |
| Sánchez Fayos, J | 1 |
| Calabuig, T | 1 |
| Torres, P | 1 |
| García Villaescusa, R | 1 |
| Pérez Saldaña, MR | 1 |
| Paniagua, G | 1 |
| Almquist, A | 1 |
| Holm, J | 1 |
| Wahlin, A | 1 |
| Niederle, N | 2 |
| Zirbes, TK | 1 |
| Schmidt, M | 1 |
| Dammasch, J | 1 |
| Meuter, BR | 1 |
| Leder, LD | 3 |
| Kloke, O | 1 |
| Tura, S | 1 |
| Knobel, B | 1 |
| Melamud, E | 1 |
| Virag, I | 1 |
| Meytes, D | 1 |
| Nand, S | 1 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 1 |
| Randi, ML | 1 |
| Rossi, C | 1 |
| Fabris, F | 1 |
| Girolami, A | 1 |
| Bundschuh, S | 1 |
| Biermann, T | 1 |
| Roessler, G | 1 |
| Wasmus, M | 1 |
| Zankovich, R | 2 |
| Schaefer, HE | 3 |
| Anderson, JE | 1 |
| Craig, F | 1 |
| Holmberg, L | 1 |
| Chauncey, T | 1 |
| Guardiola, P | 1 |
| Callander, N | 1 |
| Freytes, C | 1 |
| Gazitt, Y | 1 |
| Razvillas, B | 1 |
| Naqvi, T | 1 |
| Baumann, MA | 1 |
| Gorini, M | 1 |
| Ghizzi, A | 1 |
| Bobbio Pallavicini, E | 1 |
| Corneo, G | 1 |
| Galli, C | 1 |
| Cortellaro, M | 1 |
| De Pangher, V | 1 |
| Polli, E | 1 |
| Pettit, JE | 1 |
| Lewis, SM | 2 |
| Nicholas, AW | 1 |
| Hussain, S | 1 |
| Canellos, GP | 2 |
| Young, RC | 1 |
| Neiman, PE | 1 |
| DeVita, VT | 2 |
| Spiers, AS | 1 |
| Liew, A | 1 |
| Baikie, AG | 2 |
| Maurice, P | 1 |
| Berger, R | 1 |
| Gyger, M | 1 |
| Demidova, AV | 1 |
| Sysoeva, NA | 1 |
| Lennert, K | 1 |
| Nagai, K | 1 |
| Schwarze, EW | 1 |
| Weinstein, IM | 1 |
| Uemura, Y | 1 |
| Iwahara, Y | 1 |
| Kataoka, R | 1 |
| Muneishi, H | 1 |
| Miyoshi, I | 1 |
| Adang, RP | 1 |
| Breed, WP | 1 |
| Pagano, L | 1 |
| Teofili, L | 1 |
| Marra, R | 1 |
| Storti, S | 1 |
| Rabbitti, C | 1 |
| Leone, G | 1 |
| Bizzi, B | 1 |
| Hargrave, M | 1 |
| Gordon, S | 1 |
| Chang, JC | 1 |
| Gross, HM | 1 |
| Tosato, F | 2 |
| Fossaluzza, V | 1 |
| Bortotto, L | 1 |
| Bartolomei, P | 1 |
| Kelsey, PR | 1 |
| Geary, CG | 1 |
| Krupsky, M | 1 |
| Berrebi, A | 1 |
| Messinezy, M | 1 |
| Pearson, TC | 1 |
| Prochazka, A | 1 |
| Wetherley-Mein, G | 1 |
| Paladini, G | 1 |
| Mazzanti, G | 1 |
| Covaz, E | 1 |
| Vivacqua, RJ | 1 |
| Haurani, FI | 1 |
| Erslev, AJ | 1 |
| Licht, A | 1 |
| Many, N | 1 |
| Rachmilewitz, EA | 1 |
| Patakfalvi, A | 1 |
| Bernadou, A | 1 |
| Clauvel, JP | 1 |
| Antebi, L | 1 |
| Bilski-Pasquier, G | 1 |
| Szur, L | 1 |
| Comhaire, F | 1 |
| Van Hove, W | 1 |
| Van Ganse, W | 1 |
| Van der Straeten, M | 1 |
| Inceman, S | 1 |
| Tangün, Y | 1 |
| Maldonado, JE | 1 |
| Pintado, T | 1 |
| Pierre, RV | 1 |
| Mason, JE | 1 |
| Engelmann, C | 1 |
| Schulz, K | 1 |
| Nowotny, P | 1 |
| Konrad, H | 1 |
| Visfeldt, J | 1 |
| Franzén, S | 1 |
| Nielsen, A | 1 |
| Tribukait, B | 1 |
| Martinez, J | 1 |
| Shapiro, SS | 1 |
| Holburn, RR | 1 |
| Gärtner, U | 1 |
| Schief, A | 1 |
| Rentsch, I | 1 |
| Estevez, JM | 1 |
| Urueta, EE | 1 |
| Moran, TJ | 1 |
| Ascari, E | 1 |
| Fontana, G | 1 |
| Ward, HP | 1 |
| Block, MH | 1 |
| Wasserman, LR | 1 |
| Pegrum, GD | 1 |
| Sellei, C | 1 |
| Hoshino, T | 1 |
| Kawasaki, S | 1 |
| Okada, H | 1 |
| Yamamoto, T | 1 |
| Kimura, K | 1 |
| Stecher, G | 1 |
| Reinhardt, G | 1 |
| Brandt, L | 1 |
| Clayton, DA | 1 |
| Vinograd, J | 1 |
| Donaldson, GW | 1 |
| McArthur, M | 1 |
| Macpherson, AI | 1 |
| Richmond, J | 1 |
| Gralnick, HR | 1 |
| Harbor, J | 1 |
| Vogel, C | 1 |
| Kolarz, G | 1 |
| Pietsehmann, H | 1 |
| Regele, H | 1 |
| Komiva, NF | 1 |
| Treske, U | 1 |
| Firusian, N | 1 |
| Reis, HE | 1 |
| Gallmeier, W | 1 |
| Schmidt, CG | 1 |
| Malpas, JS | 1 |
| Eberle, P | 1 |
| Gorshein, D | 1 |
| Brauer, MJ | 1 |
| Khumbanonda, M | 1 |
| Horowitz, HI | 1 |
| Eyster, ME | 1 |
| Hooey, MA | 1 |
| Crookston, JH | 1 |
| Squires, AH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Allogeneic Stem Cell Transplantation After Dose-reduced Intensity Conditioning Regimen for Patients With Myelofibrosis With Myeloid Metaplasia (MMM): A Phase II-study[NCT00599547] | Phase 2 | 106 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| Autologous Peripheral Blood Stem Cell Mobilization and Transplantation for Myelofibrosis[NCT00006367] | Phase 2 | 0 participants | Interventional | 2000-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for busulfan and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications.
Topics: Bone Marrow Cells; Busulfan; Fibrosis; Humans; Janus Kinases; Nitriles; Primary Myelofibrosis; Progn | 2015 |
Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Topics: Busulfan; Cell Proliferation; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Acute; Nitrile | 2016 |
Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Busulfan; Ch | 2004 |
Myeloproliferative diseases in childhood.
Topics: Adolescent; Adrenal Cortex Hormones; Busulfan; Cell Transformation, Neoplastic; Child; Child, Presch | 1981 |
The management of elderly patients with myeloproliferative disorders.
Topics: Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Chronic Disease; Humans; Hydroxyure | 1993 |
Ectopic medullary hematopoiesis as a cause of ascites in agnogenic myeloid metaplasia. Case report and review of the literature.
Topics: Anemia, Hemolytic; Ascites; Biopsy; Bone Marrow; Busulfan; Combined Modality Therapy; Coombs Test; D | 1993 |
Myelofibrosis: response to busulfan after hydroxyurea failure.
Topics: Alkylating Agents; Antimetabolites; Busulfan; Gastrointestinal Hemorrhage; Humans; Hydroxyurea; Male | 2002 |
Disorders of hemostasis and thrombosis in the aged.
Topics: Adolescent; Adult; Aged; Aortic Aneurysm; Blood Coagulation Disorders; Blood Coagulation Factors; Bl | 1976 |
Patho-anatomical features of the bone marrow.
Topics: Bone Marrow; Busulfan; Diagnosis, Differential; Erythropoiesis; Granulocytes; Humans; Leukemia, Myel | 1975 |
Idiopathic myelofibrosis: historical review, diagnosis and management.
Topics: Anemia; Bone Marrow; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Diagnosis, Di | 1991 |
[Onset of polycythemia in idiopathic myelofibrosis. Description of a clinical case and review of the literature].
Topics: Adrenal Cortex Hormones; Anemia; Biopsy; Bone Marrow; Busulfan; Female; Humans; Liver; Middle Aged; | 1988 |
Management of idiopathic myelofibrosis.
Topics: Anemia; Ascites; Blood Coagulation Disorders; Bone Marrow; Busulfan; Chlorambucil; Humans; Hypertens | 1987 |
[Current therapeutic possibilities in idiopathic myelofibrosis. Observations on 47 cases].
Topics: Adrenal Cortex Hormones; Adult; Androgens; Anemia; Busulfan; Drug Synergism; Female; Humans; Leukocy | 1968 |
The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome.
Topics: Adrenal Cortex Hormones; Alkaline Phosphatase; Androgens; Anemia; Animals; Blood Cell Count; Blood C | 1971 |
The management of polycythaemia vera.
Topics: Acute Disease; Alkylating Agents; Bloodletting; Bone Marrow Diseases; Busulfan; Humans; Leukemia; Ph | 1971 |
10 trials available for busulfan and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population-based cohort study in Sweden and Norway.
Topics: Aged; Busulfan; Danazol; Disease-Free Survival; Female; Follow-Up Studies; Glucocorticoids; Humans; | 2019 |
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EB
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; | 2021 |
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.
Topics: Adult; Blood Donors; Busulfan; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Tr | 2019 |
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Middle Ag | 2009 |
Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis.
Topics: Aged; Busulfan; Cord Blood Stem Cell Transplantation; Feasibility Studies; Female; Graft Survival; H | 2010 |
Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; C | 2003 |
Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Topics: Adult; Bone Marrow Examination; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Tra | 2007 |
The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML--a comparative morphometric study on sequential trephine biopsies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biopsy; Bone Marrow; Busulfan; Female; Humans; Interfero | 1995 |
Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis.
Topics: Aged; Busulfan; Follow-Up Studies; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoie | 2001 |
Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan.
Topics: Amenorrhea; Bone Marrow Examination; Busulfan; Chromosome Aberrations; Drug Evaluation; Drug Resista | 1975 |
107 other studies available for busulfan and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis.
Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Primary Myelofibrosis; Retrospective Studies; Transp | 2022 |
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transp | 2023 |
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning.
Topics: Busulfan; Graft vs Host Disease; Humans; Methotrexate; Primary Myelofibrosis; Recurrence; Tacrolimus | 2023 |
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Primary Myelofibro | 2020 |
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Nitriles; Pr | 2020 |
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middl | 2021 |
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen.
Topics: Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic S | 2021 |
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neopl | 2021 |
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Chimerism; Female; Graft vs Host Disease; | 2019 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Allogeneic hematopoietic stem cell transplantation for infants with idiopathic myelofibrosis.
Topics: Blood Platelets; Busulfan; Child, Preschool; Cohort Studies; Cyclophosphamide; Female; Follow-Up Stu | 2013 |
Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Fe | 2014 |
Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis.
Topics: Aged; Allografts; Busulfan; Disease-Free Survival; Female; Humans; Male; Middle Aged; Primary Myelof | 2016 |
Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calreticulin; Com | 2015 |
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
Topics: Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male | 2016 |
Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Busulfan; Female; Humans; Male; M | 2016 |
[Long-term remission of non-Hodgkin lymphoma secondary to the treatment for essential thrombocythemia].
Topics: Alkylating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2009 |
Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Hemat | 2010 |
Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2011 |
Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.
Topics: Adult; Busulfan; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem | 2002 |
Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Chroni | 2003 |
Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients.
Topics: Biopsy; Bone Marrow; Busulfan; Disease Progression; Follow-Up Studies; Humans; Hydroxyurea; Interfer | 2003 |
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Topics: Acute Disease; Alkylating Agents; Busulfan; Chronic Disease; Drug Therapy, Combination; Female; Huma | 2003 |
[CHRONIC MYELOID LEUKOSIS IN CHILDREN: 4 CASES].
Topics: Blood Platelet Disorders; Busulfan; Child; Humans; Leukemia; Leukemia, Myeloid; Leukocytosis; Lymph | 1963 |
[THE ROLE OF THE PLASMA FACTOR IN LEUKOCYTOPOIESIS].
Topics: Agranulocytosis; Busulfan; Hematopoiesis; Hypersplenism; Leukemia; Leukemia, Lymphoid; Leukemoid Rea | 1963 |
MYLERAN AS A THERAPEUTIC ADJUNCT IN GASTROINTESTINAL BLEEDING COMPLICATING MYELOPROLIFERATIVE DISORDERS.
Topics: Anemia; Anemia, Hypochromic; Blood Platelet Disorders; Bone Marrow Diseases; Busulfan; Gastrointesti | 1963 |
[REPEATED THERAPY OF CHRONIC MYELOSES BY COMBINED APPLICATION OF MYLERAN AND IRRADIATION OF THE SPLEEN].
Topics: Busulfan; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Ne | 1963 |
[THERAPEUTIC SYNERGISM AS A PROBABLE EXPLANATION FOR THE COMBINED EFFECT OF X-RAY IRRADIATION AND MYLERAN IN CHRONIC MYELOSES].
Topics: Busulfan; Hemoglobinometry; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Coun | 1964 |
USE OF TESTOSTERONE AND BUSULFAN IN THE TREATMENT OF MYELOFIBROSIS WITH MYELOID METAPLASIA.
Topics: Blood Cell Count; Busulfan; Chromium Isotopes; Erythropoiesis; Geriatrics; Hematocrit; Hemoglobins; | 1964 |
[EXPERIENCE IN THE TREATMENT OF MALIGNANT DISEASES OF THE RETICULOENDOTHELIAL SYSTEM AND LEUKEMIAS. II].
Topics: Betamethasone; Busulfan; Chlorambucil; Copper; Cyclophosphamide; Dexamethasone; Genetic Diseases, X- | 1964 |
THE GRANULOCYTE RESPONSE TO ENDOTOXIN IN PATIENTS WITH HEMATOLOGIC DISORDERS.
Topics: Bone Marrow; Busulfan; Endotoxins; Granulocytes; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Mye | 1964 |
[HEMORRHAGIC THROMBOCYTHEMIA AND THE "MYELOPROLIFERATIVE SYNDROME"].
Topics: Anemia; Anemia, Hypochromic; Blood Platelets; Busulfan; Gastrointestinal Hemorrhage; Hemorrhage; Hem | 1964 |
[MODERN TREATMENT OF LEUKEMIA].
Topics: Agranulocytosis; Busulfan; Chlorambucil; Cyclophosphamide; Drug Therapy; Genetic Diseases, X-Linked; | 1965 |
ACTIVE TUBERCULOSIS IN LEUKEMIA. MALIGNANT LYMPHOMA AND MYELOFIBROSIS.
Topics: Alkylating Agents; Aminopterin; Busulfan; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leu | 1965 |
[BIOPTIC STUDIES ON THE PROBLEM OF THERAPY-INDUCED BONE MARROW FIBROSES IN CHRONIC MYELOID LEUKEMIA].
Topics: Busulfan; Drug Therapy; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia | 1965 |
[THERAPEUTIC CRITERIA OF MYELOFIBROSIS].
Topics: Androgens; Busulfan; Erythropoiesis; Humans; Primary Myelofibrosis; Splenectomy | 1964 |
Busulfan therapy in myeloid metaplasia.
Topics: Busulfan; Disease; Liver Diseases; Myeloproliferative Disorders; Primary Myelofibrosis; Spleen; Sple | 1960 |
Reversal of marrow fibrosis in agnogenic myeloid metaplasia by allogeneic peripheral blood stem cell transplantation.
Topics: Busulfan; Cyclophosphamide; Cyclosporine; Female; Granulocyte Colony-Stimulating Factor; Histocompat | 2003 |
Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Busulfan; Female; Hematopoiesis; Humans; Hydroxyurea; Inte | 2003 |
[Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; | 2004 |
Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood progenitor cell transplantation with high doses of CD34+ cells results in hematologic responses - follow-up of three patients.
Topics: Antigens, CD34; Busulfan; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; My | 2005 |
Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.
Topics: Adult; Antilymphocyte Serum; Blood Transfusion, Autologous; Busulfan; Disease-Free Survival; Female; | 2005 |
Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood progenitor cell transplantation with high doses of CD34+ cells results in hematologic responses. A follow-up of three patients.
Topics: Antigens, CD34; Antineoplastic Agents, Alkylating; Busulfan; Female; Follow-Up Studies; Humans; Peri | 2005 |
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Child, Preschool; Cyclophosphamide; Fe | 2006 |
Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Busulfan; Fatal Outcome; Humans; Imatinib Me | 2008 |
Agnogenic myeloid metaplasia. Natural history and treatment.
Topics: Adrenal Cortex Hormones; Adult; Aged; Androgens; Blood Transfusion; Busulfan; Female; Humans; Male; | 1967 |
[Therapy of chronic myeloid leukemia].
Topics: Busulfan; Chromosomes, Human, 21-22 and Y; Drug Administration Schedule; Humans; Hydroxyurea; Leukem | 1981 |
The reversal of myelofibrosis associated with chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Topics: Adult; Allopurinol; Aspirin; Bone Marrow; Bone Marrow Transplantation; Busulfan; Drug Therapy, Combi | 1983 |
1-(2-Chloroethyl)-cyclohexyl-nitrosourea-induced remission in essential thrombocythemia.
Topics: Adult; Age Factors; Aged; Alkylating Agents; Busulfan; Female; Humans; Leukemia, Myeloid, Acute; Lom | 1983 |
Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis.
Topics: Aged; Biopsy; Bone Marrow; Busulfan; Female; Humans; Liver; Male; Middle Aged; Organ Size; Primary M | 1984 |
Blastic crisis and myelofibrosis, simultaneous complications in a case of chronic myelocytic leukemia.
Topics: Adult; Bone Marrow; Busulfan; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Primary Mye | 1981 |
Concomitant myelofibrosis with agnogenic myeloid metaplasia and malignant lymphoma.
Topics: Busulfan; Humans; Lymphoma; Male; Middle Aged; Primary Myelofibrosis | 1983 |
[Malignant phase and haematological patterns of metamorphosis on seventy cases of chronic granulocytic leukaemia (author's transl)].
Topics: Bone Marrow; Busulfan; Drug Resistance; Humans; Karyotyping; Leukemia, Erythroblastic, Acute; Leukem | 1981 |
Response to busulphan treatment of paroxysmal nocturnal hemoglobinuria and myelofibrosis in one and the same patient.
Topics: Blood Cell Count; Busulfan; Female; Hemoglobinuria, Paroxysmal; Humans; Middle Aged; Primary Myelofi | 1981 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Busulfan; Disease Pro | 2000 |
Changing patterns of histological subgroups during therapy of Ph1+ chronic myelogenous leukaemia.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Busulfan; Granulocytes; Humans; Hydroxyurea; Interferon a | 2000 |
Prognostic impact of bone marrow erythropoietic precursor cells and myelofibrosis at diagnosis of Ph1+ chronic myelogenous leukaemia--a multicentre study on 495 patients.
Topics: Adult; Bone Marrow; Busulfan; Erythroid Precursor Cells; Female; Humans; Hydroxyurea; Immunohistoche | 2001 |
An unusual case of myeloproliferative disease which started with erythroderma: chronic (incomplete) panmyelosis.
Topics: Busulfan; Dermatitis, Exfoliative; Humans; Male; Middle Aged; Myeloproliferative Disorders; Primary | 1979 |
Some clinical aspects of myelofibrosis: a study of 21 patients.
Topics: Aged; Androgens; Busulfan; Female; Humans; Male; Middle Aged; Primary Myelofibrosis; Spleen; Splenec | 1977 |
Transitional myeloproliferative disorder.
Topics: Adult; Aged; Blood Cell Count; Busulfan; Female; Folic Acid; Follow-Up Studies; Humans; Iron; Male; | 1979 |
Neutrophil alkaline phosphatase score in chronic granulocytic leukaemia: effects of splenectomy and antileukaemic drugs.
Topics: Alkaline Phosphatase; Bone Marrow Cells; Busulfan; Chronic Disease; Clinical Enzyme Tests; Histocyto | 1975 |
[The treatment of myeloproliferative syndromes].
Topics: Aged; Bloodletting; Busulfan; Chlorambucil; Female; Humans; Leukemia, Myeloid; Male; Myeloproliferat | 1975 |
[New chromosome abnormality in chronic myeloid leukemia].
Topics: Bone Marrow; Bone Marrow Cells; Busulfan; Chromosome Aberrations; Chromosome Deletion; Chromosomes, | 1976 |
[Tactics of cytostatic therapy of primary and secondary (post-erythremic) myelofibrosis].
Topics: Adult; Aged; Antineoplastic Agents; Azirines; Busulfan; Female; Humans; Leukemia, Erythroblastic, Ac | 1976 |
[Successful treatment of primary myelofibrosis by busulfan pulse therapy: report of a case].
Topics: Bone Marrow; Busulfan; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; | 1990 |
[Liver damage during use of busulfan].
Topics: Busulfan; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Humans; Male; Middle Ag | 1989 |
Remission of chronic idiopathic myelofibrosis to busulphan treatment.
Topics: Busulfan; Chronic Disease; Humans; Primary Myelofibrosis | 1989 |
Effect of chemotherapy on tear drop poikilocytes and other peripheral blood findings in myelofibrosis.
Topics: Aged; Aged, 80 and over; Allopurinol; Busulfan; Drug Therapy, Combination; Erythrocyte Count; Erythr | 1988 |
Remission of chronic idiopathic myelofibrosis to busulfan treatment.
Topics: Aged; Biopsy; Bone Marrow; Busulfan; Chronic Disease; Drug Evaluation; Female; Humans; Male; Middle | 1988 |
[Acute leukemia secondary to idiopathic myelofibrosis with homozygote pseudo-Pelger anomaly and complex chromosomal changes].
Topics: Aged; Busulfan; Chromosome Aberrations; Chromosomes, Human, 13-15; Female; Homozygote; Humans; Karyo | 1986 |
[Essential thrombocythemia].
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Busulfan; Humans; Middle Aged; Platelet Aggregation; Pr | 1987 |
Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre.
Topics: Adult; Aged; Bloodletting; Busulfan; Female; Humans; Male; Middle Aged; Polycythemia Vera; Primary M | 1985 |
[Development of polycythemia vera during chronic idiopathic myelofibrosis].
Topics: Adult; Anemia, Myelophthisic; Busulfan; Chronic Disease; Hepatomegaly; Humans; Male; Platelet Count; | 1985 |
"Selective" pituitary insufficiency secondary to busulfan.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenal Insufficiency; Adrenocorticotropic Hormone; Aged | 1967 |
Myelofibrosis, osteolytic bone lesions and hypercalcemia in chronic myeloid leukemia.
Topics: Adult; Bone Resorption; Busulfan; Female; Humans; Hypercalcemia; Leukemia, Myeloid; Primary Myelofib | 1973 |
Secondary antibody deficiency syndrome in haemoblastosis.
Topics: Agammaglobulinemia; Antibodies; Antigens, Bacterial; Blood Protein Disorders; Blood Proteins; Busulf | 1972 |
[Vaquez's diseas. Clinical and developmental study. Apropos of 144 cases].
Topics: Adult; Arteriosclerosis; Arteritis; Blood Sedimentation; Busulfan; Child; Erythrocyte Count; Female; | 1968 |
Blood and neoplastic diseases. Myeloproliferative disorders.
Topics: Adrenal Cortex Hormones; Androgens; Blood Transfusion; Bloodletting; Busulfan; Chlorambucil; Cycloph | 1974 |
Busulphan and the lungs. Absence of lung function disturbance in patients treated with busulphan.
Topics: Adult; Aged; Busulfan; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Mi | 1972 |
Platelet defects in the myeloproliferative disorders.
Topics: Adenosine Diphosphate; Adult; Aged; Blood Coagulation Tests; Blood Platelets; Busulfan; Densitometry | 1972 |
Dysplastic platelets and circulating megakaryocytes in chronic myeloproliferative diseases. I. The platelets: ultrastructure and peroxidase reaction.
Topics: Adult; Aged; Blood Coagulation Tests; Blood Platelets; Bone Marrow Examination; Busulfan; Chromosome | 1974 |
Chronic granulocytic leukaemia.
Topics: Adult; Busulfan; Child; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Chronic Disease; Di | 1974 |
Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance.
Topics: Anemia; Azauridine; Blood Cell Count; Blood Platelets; Bone Marrow Examination; Busulfan; Cell Trans | 1974 |
[Indications for cytostatic treatment of patients with osteomyelosclerosis of osteomyelofibrosis].
Topics: Adult; Aged; Antineoplastic Agents; Azathioprine; Busulfan; Female; Humans; Male; Mannitol; Mercapto | 1972 |
Primary polycythaemia. 3. Studies on the significance of the history of the disease and of the treatment for the development of clones in bone marrow cells.
Topics: Adult; Aged; Bone Marrow; Bone Marrow Cells; Busulfan; Cell Transformation, Neoplastic; Clone Cells; | 1973 |
Metabolism of human prothrombin and fibrinogen in patients with thrombocytosis secondary to myeloproliferative states.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Blood Cell Count; Blood Coagulation Factors; Blood Co | 1973 |
[Myelofibrosis and leukemia (author's transl)].
Topics: Adolescent; Adult; Alkaline Phosphatase; Busulfan; Female; Glucosephosphate Dehydrogenase; Humans; L | 1973 |
Acute megakaryocytic myelofibrosis. Case report of an unusual myeloproliferative syndrome.
Topics: Acute Disease; Adrenal Gland Neoplasms; Autopsy; Bone Marrow; Bone Marrow Cells; Busulfan; Female; H | 1974 |
Stimulation in vitro of cells from patients with myeloproliferative disorders.
Topics: Autoradiography; Bone Marrow Diseases; Busulfan; Culture Techniques; Humans; Lectins; Leukemia, Myel | 1967 |
Treatment of myeloproliferative diseases.
Topics: Busulfan; Humans; Leukemia, Myeloid; Mannitol; Myeloproliferative Disorders; Polycythemia Vera; Prim | 1966 |
Polycythemia vera terminating in acute myelogenous leukemia with fibrosis of bone marrow: case report.
Topics: Acute Disease; Aged; Busulfan; Female; Humans; Leukemia, Myeloid; Polycythemia; Primary Myelofibrosi | 1967 |
Chemotherapy in polycythemia vera.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid; Phosphorus Isotopes; Polycythemia Vera; Primary Myelo | 1968 |
Studies on the phagocytic activity of neutrophilic leukocytes.
Topics: Adult; Age Factors; Aged; Alkaline Phosphatase; Anemia, Macrocytic; Animals; Biopsy; Bone Marrow Dis | 1967 |
Complex mitochondrial DNA in leukemic and normal human myeloid cells.
Topics: Busulfan; DNA; Humans; Leukemia, Myeloid; Leukemoid Reaction; Leukocytes; Mercaptopurine; Methods; M | 1969 |
Blood volume changes in splenomegaly.
Topics: Adolescent; Adult; Aged; Anemia; Blood Volume; Busulfan; Chromium Isotopes; Female; Hematocrit; Huma | 1970 |
Myelofibrosis in chronic granulocytic leukemia.
Topics: Adolescent; Adult; Alkaline Phosphatase; Anemia; Bone Marrow Examination; Busulfan; Chromosome Aberr | 1971 |
[Lung changes under busulfan therapy in a case of chronic myelosis].
Topics: Busulfan; Chronic Disease; Female; Humans; Leukocyte Count; Lung; Lung Diseases; Middle Aged; Primar | 1970 |
[Myelobromel in the treatment of patients with idiopathic myelofibrosis during erythremic phase].
Topics: Busulfan; Carbohydrates; Female; Humans; Male; Polycythemia; Primary Myelofibrosis | 1970 |
[Therapy of osteomyelosclerosis and osteomyelofibrosis].
Topics: Anemia, Myelophthisic; Busulfan; Humans; Primary Myelofibrosis; Splenectomy | 1970 |
[Syntropy of malignant diseases with hemoblastosis].
Topics: Adenocarcinoma; Aged; Busulfan; Estradiol; Female; Humans; Immunosuppressive Agents; Kidney Neoplasm | 1970 |
Myelofibrosis.
Topics: Busulfan; Female; Humans; Middle Aged; Primary Myelofibrosis | 1968 |
[Myleran and damage to spermatozoa in man].
Topics: Adult; Busulfan; Humans; Infertility, Male; Male; Primary Myelofibrosis; Spermatozoa | 1969 |
Ascites in myeloid metaplasia due to ectopic peritoneal implantations.
Topics: Ascites; Ascitic Fluid; Biopsy; Busulfan; Humans; Male; Middle Aged; Peritoneal Diseases; Peritoneum | 1969 |
Coombs' positive hemolytic anemia in myelofibrosis with myeloid metaplasia.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Busulfan; Coombs Test; Female; Humans; Male; Middle Aged; Pred | 1969 |
Myeloproliferative disease complicated by megaloblastic anemia and hyperuricemia.
Topics: Anemia, Macrocytic; Blood; Blood Coagulation Disorders; Busulfan; Enzyme Therapy; Epistaxis; Female; | 1965 |